Trovagene Announces Adjournment of Special Meeting of Stockholders Until February 12, 2019

[In The News]

SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers,...

View the full article